Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Colorcon
Harvard Business School
McKinsey
Mallinckrodt

Last Updated: May 17, 2022

AMYVID Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Amyvid patents expire, and what generic alternatives are available?

Amyvid is a drug marketed by Avid Radiopharms Inc and is included in one NDA. There are two patents protecting this drug.

This drug has forty-nine patent family members in thirty-two countries.

The generic ingredient in AMYVID is florbetapir f-18. One supplier is listed for this compound. Additional details are available on the florbetapir f-18 profile page.

DrugPatentWatch® Generic Entry Outlook for Amyvid

Amyvid was eligible for patent challenges on April 6, 2016.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 30, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Summary for AMYVID
International Patents:49
US Patents:2
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 7
Clinical Trials: 38
Patent Applications: 248
What excipients (inactive ingredients) are in AMYVID?AMYVID excipients list
DailyMed Link:AMYVID at DailyMed
Drug patent expirations by year for AMYVID
DrugPatentWatch® Estimated Generic Entry Opportunity Date for AMYVID
Generic Entry Date for AMYVID*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for AMYVID

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
InvicroPhase 1
Elisa KonofagouN/A
National Institute on Aging (NIA)N/A

See all AMYVID clinical trials

Pharmacology for AMYVID

US Patents and Regulatory Information for AMYVID

AMYVID is protected by two US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of AMYVID is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting AMYVID

Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: AMYVID IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE BETA-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Avid Radiopharms Inc AMYVID florbetapir f-18 SOLUTION;INTRAVENOUS 202008-001 Apr 6, 2012 DISCN No No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Avid Radiopharms Inc AMYVID florbetapir f-18 SOLUTION;INTRAVENOUS 202008-002 Apr 6, 2012 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Avid Radiopharms Inc AMYVID florbetapir f-18 SOLUTION;INTRAVENOUS 202008-001 Apr 6, 2012 DISCN No No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Avid Radiopharms Inc AMYVID florbetapir f-18 SOLUTION;INTRAVENOUS 202008-002 Apr 6, 2012 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Avid Radiopharms Inc AMYVID florbetapir f-18 SOLUTION;INTRAVENOUS 202008-003 Apr 6, 2012 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Avid Radiopharms Inc AMYVID florbetapir f-18 SOLUTION;INTRAVENOUS 202008-003 Apr 6, 2012 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for AMYVID

When does loss-of-exclusivity occur for AMYVID?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 07243712
Estimated Expiration: See Plans and Pricing

Austria

Patent: 9060
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 0710225
Estimated Expiration: See Plans and Pricing

Canada

Patent: 44530
Estimated Expiration: See Plans and Pricing

China

Patent: 1522624
Estimated Expiration: See Plans and Pricing

Costa Rica

Patent: 329
Estimated Expiration: See Plans and Pricing

Croatia

Patent: 0120135
Estimated Expiration: See Plans and Pricing

Patent: 0170857
Estimated Expiration: See Plans and Pricing

Cyprus

Patent: 13048
Estimated Expiration: See Plans and Pricing

Patent: 19048
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 99109
Estimated Expiration: See Plans and Pricing

Patent: 63392
Estimated Expiration: See Plans and Pricing

Ecuador

Patent: 088783
Estimated Expiration: See Plans and Pricing

Eurasian Patent Organization

Patent: 7898
Estimated Expiration: See Plans and Pricing

Patent: 0870389
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 99109
Estimated Expiration: See Plans and Pricing

Patent: 63391
Estimated Expiration: See Plans and Pricing

Patent: 63392
Estimated Expiration: See Plans and Pricing

Guatemala

Patent: 0800201
Estimated Expiration: See Plans and Pricing

Hungary

Patent: 32660
Estimated Expiration: See Plans and Pricing

Patent: 300028
Estimated Expiration: See Plans and Pricing

Israel

Patent: 3567
Estimated Expiration: See Plans and Pricing

Japan

Patent: 90954
Estimated Expiration: See Plans and Pricing

Patent: 09532349
Estimated Expiration: See Plans and Pricing

Lithuania

Patent: 63392
Estimated Expiration: See Plans and Pricing

Luxembourg

Patent: 232
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 08012527
Estimated Expiration: See Plans and Pricing

New Zealand

Patent: 0887
Estimated Expiration: See Plans and Pricing

Norway

Patent: 2090
Estimated Expiration: See Plans and Pricing

Patent: 18030
Estimated Expiration: See Plans and Pricing

Patent: 084590
Estimated Expiration: See Plans and Pricing

Poland

Patent: 99109
Estimated Expiration: See Plans and Pricing

Patent: 63392
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 99109
Estimated Expiration: See Plans and Pricing

Patent: 63392
Estimated Expiration: See Plans and Pricing

Serbia

Patent: 222
Estimated Expiration: See Plans and Pricing

Patent: 171
Estimated Expiration: See Plans and Pricing

Singapore

Patent: 3338
Estimated Expiration: See Plans and Pricing

Slovenia

Patent: 99109
Estimated Expiration: See Plans and Pricing

Patent: 63392
Estimated Expiration: See Plans and Pricing

South Africa

Patent: 0807955
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 1376807
Estimated Expiration: See Plans and Pricing

Patent: 080106564
Estimated Expiration: See Plans and Pricing

Spain

Patent: 78785
Estimated Expiration: See Plans and Pricing

Patent: 28882
Estimated Expiration: See Plans and Pricing

Taiwan

Patent: 99366
Estimated Expiration: See Plans and Pricing

Patent: 0838852
Estimated Expiration: See Plans and Pricing

Ukraine

Patent: 802
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering AMYVID around the world.

Country Patent Number Title Estimated Expiration
Portugal 1999109 See Plans and Pricing
Taiwan I399366 See Plans and Pricing
Mexico 2008012527 DERIVADOS DE ESTIRILPIRIDINA Y SUS USOS PARA UNION A PLACAS AMILOIDES Y OBTENCION DE IMAGENES DE LAS MISMAS. (STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES.) See Plans and Pricing
Ukraine 97802 СТИРИЛПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ ДЛЯ СВЯЗЫВАНИЯ И ВИЗУАЛИЗАЦИИ АМИЛОИДНЫХ БЛЯШЕК;СТИРИЛПІРИДИНОВІ ПОХІДНІ І ЇХ ЗАСТОСУВАННЯ ДЛЯ ЗВ'ЯЗУВАННЯ І ВІЗУАЛІЗАЦІЇ АМІЛОЇДНИХ БЛЯШОК (STYRYLPYRIDINE COMPOUNDS USEFUL AND USE THEREOF IN IMAGING AMYLOID DEPOSITS) See Plans and Pricing
Spain 2628882 See Plans and Pricing
Spain 2378785 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for AMYVID

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1999109 2013/028 Ireland See Plans and Pricing PRODUCT NAME: FLORBETAPIR (18F), OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT; REGISTRATION NO/DATE: EU/1/12/805 20130114
1999109 139 5017-2013 Slovakia See Plans and Pricing PRODUCT NAME: FLORBETAPIR ( 18 F); REGISTRATION NO/DATE: EU/1/12/805 20130114
1999109 PA2013016 Lithuania See Plans and Pricing PRODUCT NAME: FLORBETAPIRUM; REGISTRATION NO/DATE: EU/1/12/805 20130114
1999109 SPC/GB13/040 United Kingdom See Plans and Pricing PRODUCT NAME: FLORBETAPIR (18F) ((E)-4-(2-(6-(2-(2-(2-((18F)-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL(18F); REGISTERED: UK EU/1/12/805 20130117 )VINYL)-N-METHYL BENZENAMINE) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY FLORBETAPIR
1999109 92232 Luxembourg See Plans and Pricing PRODUCT NAME: FLORBETAPIR (18 F)
1999109 C300600 Netherlands See Plans and Pricing PRODUCT NAME: FLORBETAPIR ( SUP 18 /SUP F); REGISTRATION NO/DATE: EU/1/12/805 20130114
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Harvard Business School
Medtronic
Mallinckrodt
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.